The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

被引：0

作者：

Mercer, Louise ^{[1
]}

Abhishek, Abhishek ^{[2
,3
]}

Kavirayani, Akhila ^{[4
]}

Ahmed, Alison ^{[5
]}

Davidson, Alan ^{[6
]}

Foulkes, Amy ^{[7
]}

Jones, Claire ^{[8
]}

Nash, Clare ^{[9
]}

Rose-Parfitt, Emily ^{[10
]}

Dhillon, Emmandeep ^{[11
]}

Zabate, Genevieve ^{[12
]}

Twohig, Helen ^{[13
]}

De Vere, Hope ^{[14
]}

Scott, Jennifer ^{[15
]}

Reynolds, John ^{[16
]}

Holmes, Julia ^{[17
]}

Hartley, Karen ^{[17
]}

Warrier, Kishore ^{[18
]}

Nowak, Kataryzna ^{[19
]}

Parsons, Kate ^{[20
]}

Bechman, Katie ^{[21
]}

Bray, Lisa ^{[22
]}

Adikari, Madura ^{[23
]}

Wood, Natasha ^{[24
]}

Faithfull, Nicola ^{[25
]}

Gullick, Nicola ^{[26
]}

Saha, Pratyasha ^{[27
]}

Heaton, Rebecca ^{[28
]}

Deepak, Samundeeswari ^{[29
]}

Hider, Samantha ^{[13
,30
]}

Khalid, Sameena ^{[31
]}

Said, Sanaa Suleiman ^{[32
]}

Ryan, Sarah ^{[33
]}

Kyle, Stuart ^{[34
]}

Raghuvanshi, Subhra ^{[35
]}

Tan, Su-Yin ^{[36
]}

Shivamurthy, Vinay ^{[37
]}

Galloway, James ^{[21
]}

机构：

[1] Stockport NHS Fdn Trust, Stepping Hill Hosp, Dept Rheumatol, Stockport, England

[2] Univ Nottingham, City Hosp Nottingham, Acad Rheumatol, Nottingham, England

[3] Nottingham NIHR BRC, Nottingham, England

[4] Oxford Univ Hosp NHS Fdn Trust, Nuffield Orthopaed Ctr, Paediat Rheumatol, Oxford, England

[5] Tameside & Glossop Integrated Care NHS Fdn Trust, Dept Rheumatol, Ashton Under Lyne, England

[6] Modality LLP, Community Rheumatol, Birmingham, England

[7] Salford Royal NHS Fdn Trust, Dept Dermatopharmacol, Salford, England

[8] Powys Teaching Hlth Board, Med Management, Brecon, Powys, England

[9] Sheffield Childrens NHS Fdn Trust, Pharm Dept, Sheffield, England

[10] North Bristol NHS Trust, Southmead Hosp, Dept Rheumatol, Bristol, England

[11] Royal Wolverhampton NHS Trust, New Cross Hosp, Dept Rheumatol, Wolverhampton, England

[12] Western Gen Hosp NHS Lothian, Rheumat Dis Unit, Edinburgh, Scotland

[13] Keele Univ, Sch Med, Keele, England

[14] Gloucestershire Hosp NHS Fdn Trust, Dept Rheumatol, Gloucester, England

[15] Stockport NHS Fdn Trust, Stepping Hill Hosp, Dept Hepatol & Gastroenterol, Stockport, England

[16] Univ Birmingham, Res Labs, Queen Elizabeth Hosp, Inst Inflammat & Ageing, Birmingham, England

[17] Newcastle Tyne Hosp NHS Fdn Trust, Dept Pharm, Newcastle, England

[18] Nottingham Univ Hosp NHS Trust, Nottingham Childrens Hosp, Paediat & Adolescent Rheumatol, Nottingham, England

[19] Belfast Hlth & Social Care Trust, Dept Rheumatol, Belfast, North Ireland

[20] Expert Experience, Guildford, England

[21] Kings Coll London, Ctr Rheumat Dis, London, England

[22] St Richards Hosp, Dept Paediat, Chichester, England

[23] Rotherham NHS Fdn Trust, Rotherham Gen Hosp, Dept Rheumatol, Rotherham, England

[24] Brannam Med Ctr, Barnstaple, England

[25] Birmingham Childrens Hosp, Childhood Arthrit & Rheumat Dis Unit, Birmingham, England

[26] Univ Hosp Coventry & Warwickshire, Dept Rheumatol, Coventry, England

[27] Norfolk & Norwich Univ Hosp, Dept Rheumatol, Norfolk, England

[28] Stockport NHS Fdn Trust, Dept Rheumatol, Stockport, England

[29] Nottingham Univ Hosp NHS Trust, Nottingham Childrens Hosp, Paediat & Adolescent Rheumatol, Nottingham, England

[30] Midlands Partnership Fdn Trust, Haywood Hosp, Dept Rheumatol, Stoke On Trent, England

[31] Sheffield Teaching Hosp, Royal Hallamshire Hosp, Rheumatol, Sheffield, England

[32] State Univ Zanzibar, Dept Internal Med, Tunguu, Zanzibar, Tanzania

[33] Midlands Partnership Univ NHS Fdn Trust, Dept Rheumatol, Stoke On Trent, England

[34] Royal Devon Univ, North Devon Dist Hosp, Dept Rheumatol, Devon, England

[35] Betsi Cadwaladr Univ Hlth, Wrexham Maelor Hosp, Dept Rheumatol, Wrexham, Wales

[36] NHS Tayside, Dept Rheumatol, Dundee, Scotland

[37] Guys & St Thomas NHS Fdn Trust, Evelina London Childrens Hosp, Dept Rheumatol, London, England

来源：

RHEUMATOLOGY ADVANCES IN PRACTICE | 2024年 / 8卷 / 03期

关键词：

DMARD management guideline;

D O I：

10.1093/rap/rkae077

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023. What does this mean for patients?A revised guideline, produced by the British Society for Rheumatology (BSR), will provide up-to-date information about the safe prescribing and monitoring of the effects of non-biologic (or conventional synthetic) disease-modifying anti-rheumatic drugs (DMARDs). This guideline will be used by healthcare professionals, people living with autoimmune rheumatic diseases and other interested parties, such as patient groups and charities. DMARDs are a group of drugs prescribed to people with autoimmune rheumatic diseases. The main aims of these drugs are to control symptoms and reduce or prevent long-term progression of the disease. Biologic drugs and Janus kinase inhibitors-sometimes referred to as biologic DMARDs and targeted synthetic DMARDs, respectively-are excluded from this guideline. This article outlines the scope of the revised guideline for DMARD safety, which will be updated to include new information and is being extended to include children and young people. Guideline revisions will be undertaken by a working group of adult and paediatric and adolescent rheumatologists, other healthcare professionals and people living with autoimmune rheumatic disease. The guideline will be developed using the methods and processes outlined in the BSR document 'Creating clinical guidelines: our protocol'.

引用

页数：5

共 50 条

[1] GUIDELINE ON CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Galloway, James
[J]. RHEUMATOLOGY, 2016, 55 : 14 - 14
[2] The new British Society for Rheumatology disease modifying anti-rheumatic drugs guidelines
Deighton, Chris
Gadsby, Kate
[J]. MUSCULOSKELETAL CARE, 2006, 4 (03) : 174 - 181
[3] BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
Ledingham, Jo
Gullick, Nicola
Irving, Katherine
Gorodkin, Rachel
Aris, Melissa
Burke, Jean
Gordon, Patrick
Christidis, Dimitrios
Galloway, Sarah
Hayes, Eranga
Jeffries, Andrew
Mercer, Scott
Mooney, Janice
van Leuven, Sander
Galloway, James
[J]. RHEUMATOLOGY, 2017, 56 (06) : 865 - 868
[4] Prescribing anti-rheumatic drugs in pregnancy and breastfeeding-the British Society for Rheumatology guideline scope
Pazmino, Sofia
Westhovens, Rene
De Cock, Diederik
Verschueren, Patrick
[J]. RHEUMATOLOGY, 2022, 61 (02) : 480 - 481
[5] Prescribing anti-rheumatic drugs in pregnancy and breastfeeding-the British Society for Rheumatology guideline scope
Giles, Ian
Allen, Alexander
Crossley, Amy
Flint, Julia
Frishman, Margreta
Gayed, Mary
Kamashta, Munther
Moore, Louise
Panchal, Sonia
Piper, Madeline
Reid, Clare
Saxby, Katherine
Schreiber, Karen
Senvar, Naz
Tosounidou, Sofia
van de Venne, Maud
Warburton, Louise
Wiliams, David
Yee, Chee-Seng
Gordon, Caroline
[J]. RHEUMATOLOGY, 2021, 60 (08) : 3565 - 3569
[6] Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees
Tsakas, James J.
Liew, David F. L.
Adams, Cameron L.
Hill, Catherine L.
Proudman, Susanna
Whittle, Samuel
Buchbinder, Rachelle
Robinson, Philip C.
[J]. BMC RHEUMATOLOGY, 2022, 6 (01)
[7] Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees
James J. Tsakas
David F. L. Liew
Cameron L. Adams
Catherine L. Hill
Susanna Proudman
Samuel Whittle
Rachelle Buchbinder
Philip C. Robinson
[J]. BMC Rheumatology, 6
[8] The use of conventional disease-modifying anti-rheumatic drugs in established RA
Jurgens, M. S.
Jacobs, J. W. G.
Bijlsma, J. W. J.
[J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2011, 25 (04): : 523 - 533
[9] Pharmacogenetics of disease-modifying anti-rheumatic drugs
Tanaka, E
Taniguchi, A
Urano, W
Yamanaka, H
Kamatani, N
[J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
[10] Disease-modifying anti-rheumatic drugs - Cyclosporin
Chaudhuri, K
Torley, H
Madhok, R
[J]. BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (09): : 1016 - 1021

← 1 2 3 4 5 →